Madaus Martin D
SEC CIK 1310268 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AZTA | Azenta, Inc. | Interim CEO | 42.6K | $201.4K | — | 4 | 2024-02-12 | 2026-09-22 |
| HAE | HAEMONETICS CORP | Dir | 2,538 | — | — | 1 | 2026-07-24 | 2026-07-24 |
| RGEN | REPLIGEN CORP | Dir | 6,581 | $641.9K | — | 9 | 2023-02-06 | 2026-05-14 |
| QTRX | Quanterix Corp | Dir | 36.9K | $755.9K | — | 7 | 2021-07-01 | 2025-01-02 |
| LAB | STANDARD BIOTOOLS INC. | Dir | 104.1K | — | — | 5 | 2022-04-04 | 2023-10-20 |
Most active insiders at AZTA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Cornog William L | Dir | $163.8K | — |
| 2 | Starr Ephraim | SVP, Gen Counsel, Sec | $8,096 | — |
| 3 | Bello Erik J. | VP CAO | — | — |
| 4 | Lin Lawrence Y. | EVP, CFO, Treas | — | — |
| 5 | Pirogova Olga | SVP, CHRO | — | — |
| 6 | Koffey Quentin | Dir | — | — |
| 7 | Zhou Ginger | SVP, GM, Multiomics | — | — |
| 8 | MARTIN WILLIAM E. III | Pres Multiomics | — | — |
| 9 | Casal Frank | Dir | — | — |
| 10 | Marotta John | Pres, CEO, Dir | — | — |
| 13 | Madaus Martin D | Interim CEO | — | — |
Transactions 26
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-23 10:24 | 2026-09-22 | AZTA | Azenta, Inc. | Madaus Martin D | Interim CEO | F - Tax | $34.28 | -1,456 | 42.6K | -3% | -$49.9K | |
| 2026-09-16 21:50 | 2026-09-14 | AZTA | Azenta, Inc. | Madaus Martin D | Interim CEO | A - Grant | $0.00 | +36.7K | 44.1K | +495% | $0 | |
| 2026-07-28 17:04 | 2026-07-24 | HAE | HAEMONETICS CORP | Madaus Martin D | Dir | A - Grant | — | +2,538 | 2,538 | New | — | |
| D | 2026-05-18 16:05 | 2026-05-14 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | A - Grant | $0.00 | +995 | 6,581 | +18% | $0 |
| I | 2025-08-12 | 2025-08-08 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | P - Purchase | $112.13 | +1,800 | 1,800 | New | +$201.8K |
| D | 2025-05-19 | 2025-05-15 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | A - Grant | $0.00 | +973 | 5,586 | +21% | $0 |
| D | 2025-01-06 | 2025-01-02 | QTRX | Quanterix Corp | Madaus Martin D | Dir | A - Grant | $0.00 | +7,435 | 36.9K | +25% | $0 |
| 2024-11-19 | 2024-11-19 | AZTA | Azenta, Inc. | Madaus Martin D | Dir | P - Purchase | $40.77 | +4,940 | 7,405 | +200% | +$201.4K | |
| M | 2024-06-14 | 2024-06-14 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | P - Purchase | $124.94 | +1,615 | 4,613 | +54% | +$201.8K |
| D | 2024-05-20 | 2024-05-16 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | A - Grant | $0.00 | +701 | 2,998 | +31% | $0 |
| 2024-02-13 | 2024-02-12 | AZTA | Azenta, Inc. | Madaus Martin D | Dir | A - Grant | $65.93 | +2,465 | 2,465 | New | +$162.5K | |
| D | 2024-01-04 | 2024-01-02 | QTRX | Quanterix Corp | Madaus Martin D | Dir | A - Grant | $0.00 | +2,947 | 29.5K | +11% | $0 |
| 2023-10-20 | 2023-10-20 | LAB | STANDARD BIOTOOLS INC. | Madaus Martin D | Dir | A - Grant | $2.54 | +1,574 | 104.1K | +2% | +$3,998 | |
| D | 2023-06-16 | 2023-06-14 | LAB | STANDARD BIOTOOLS INC. | Madaus Martin D | Dir | A - Grant | $0.00 | +26.4K | 102.5K | +35% | $0 |
| D | 2023-05-22 | 2023-05-18 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | A - Grant | $0.00 | +686 | 2,297 | +43% | $0 |
| M | 2023-05-08 | 2023-05-04+ | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | P - Purchase | $158.84 | +1,500 | 611 | New | +$238.3K |
| I | 2023-05-08 | 2023-03-24 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | L - Small Acq | $186.22 | +11 | 11 | New | +$2,048 |
| 2023-02-22 | 2023-02-20 | LAB | STANDARD BIOTOOLS INC. | Madaus Martin D | Dir | A - Grant | $0.00 | +29.7K | 76.2K | +64% | $0 | |
| D | 2023-02-08 | 2023-02-06 | RGEN | REPLIGEN CORP | Madaus Martin D | Dir | A - Grant | $0.00 | +111 | 111 | New | $0 |
| D | 2023-01-04 | 2023-01-03 | QTRX | Quanterix Corp | Madaus Martin D | Dir | A - Grant | $0.00 | +8,083 | 26.5K | +44% | $0 |
| I | 2022-08-10 | 2022-08-10 | QTRX | Quanterix Corp | Madaus Martin D | Dir | P - Purchase | $8.43 | +89.7K | 254.6K | +54% | +$755.9K |
| D | 2022-06-17 | 2022-06-15 | LAB | STANDARD BIOTOOLS INC. | Madaus Martin D | Dir | A - Grant | $0.00 | +30.9K | 46.8K | +195% | $0 |
| D | 2022-04-06 | 2022-04-04 | LAB | STANDARD BIOTOOLS INC. | Madaus Martin D | Dir | A - Grant | $0.00 | +15.9K | 15.9K | New | $0 |
| DM | 2022-01-05 | 2022-01-03 | QTRX | Quanterix Corp | Madaus Martin D | Dir | A - Grant | $5.85 | +3,095 | 18.4K | +20% | +$18.1K |
| 2021-10-05 | 2021-10-01 | QTRX | Quanterix Corp | Madaus Martin D | Dir | A - Grant | $51.18 | +354 | 15.3K | +2% | +$18.1K | |
| 2021-07-06 | 2021-07-01 | QTRX | Quanterix Corp | Madaus Martin D | Dir | A - Grant | $59.48 | +304 | 15.0K | +2% | +$18.1K |
Purchase Sale Sale after option exercise All abbreviations